At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 65 enrolled
Drug / intervention
Liposome Bupivacaine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Liposomal Bupivacaine for Total Knee Arthroplasty Postoperative Analgesia
In Brief
A Phase 4 clinical trial evaluating Liposome Bupivacaine and Bupivacaine HCl for Post-operative Pain. Completed, enrolled 65 participants across 1 site.
Detailed Summary
Continuous femoral nerve blocks (CFNB) provide effective pain control to patients undergoing total knee replacement (TKR). However the resulting motor blockade can lead to decreased quadriceps muscle strength and delayed functional recovery.The purpose of this study is to compare the effect of Liposome Bupivacaine infiltration into the knee to CFNB on pain control and functional recovery
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost-operative Pain
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartNov 2014
Primary CompletionDec 2016
Study CompletionJan 2017
TodayJul 2026
First PostedOct 24, 2014
Enrollment StartNov 1, 2014
Primary CompletionDec 1, 2016
Study CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.7 years ago
Interventions
Liposome Bupivacainedrug
Administered via local tissue infiltration around the knee joint
Bupivacaine HCldrug
Administered via CFNB